318 related articles for article (PubMed ID: 31814080)
21. Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pouwels XGLV; Wolff R; Ramaekers BLT; Van Giessen A; Lang S; Ryder S; Worthy G; Duffy S; Armstrong N; Kleijnen J; Joore MA
Pharmacoeconomics; 2018 May; 36(5):533-543. PubMed ID: 29344794
[TBL] [Abstract][Full Text] [Related]
22. Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective.
Dunlop W; van Keep M; Elroy P; Perez ID; Ouwens MJNM; Sarbajna T; Zhang Y; Greystoke A
Pharmacoecon Open; 2022 Mar; 6(2):241-252. PubMed ID: 34532842
[TBL] [Abstract][Full Text] [Related]
23. Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal.
Pennington B; Ren S; Barton S; Bacelar M; Edwards SJ
Pharmacoeconomics; 2019 Aug; 37(8):985-993. PubMed ID: 30465228
[TBL] [Abstract][Full Text] [Related]
24. Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Simpson E; Hamilton J; Pollard D; Clowes M; Kaltenthaler E; Meiklejohn D; Morley N
Pharmacoeconomics; 2019 Mar; 37(3):333-343. PubMed ID: 30246228
[TBL] [Abstract][Full Text] [Related]
25. Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Grimm SE; Fayter D; Ramaekers BLT; Petersohn S; Riemsma R; Armstrong N; Pouwels X; Witlox W; Noake C; Worthy G; Kleijnen J; Joore MA
Pharmacoeconomics; 2019 Oct; 37(10):1195-1207. PubMed ID: 30895564
[TBL] [Abstract][Full Text] [Related]
26. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.
Wade R; Duarte A; Simmonds M; Rodriguez-Lopez R; Duffy S; Woolacott N; Spackman E
Pharmacoeconomics; 2015 May; 33(5):457-66. PubMed ID: 25616671
[TBL] [Abstract][Full Text] [Related]
27. Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Harnan S; Ren S; Thokala P; Wong R; Mukuria C; Green C; Pledge S; Tidy J
Pharmacoeconomics; 2017 Jan; 35(1):97-109. PubMed ID: 27506954
[TBL] [Abstract][Full Text] [Related]
28. Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ramaekers BLT; Riemsma R; Grimm S; Fayter D; Deshpande S; Armstrong N; Witlox W; Pouwels X; Duffy S; Worthy G; Kleijnen J; Joore MA
Pharmacoeconomics; 2019 Jul; 37(7):887-894. PubMed ID: 30426463
[TBL] [Abstract][Full Text] [Related]
29. Ibrutinib for Treating Waldenström's Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Carroll C; Stevens J; Simpson E; Thokala P; Wong R; Wright J; Auer R
Pharmacoeconomics; 2019 Jan; 37(1):7-18. PubMed ID: 29951793
[TBL] [Abstract][Full Text] [Related]
30. Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pouwels XGLV; Petersohn S; Carrera VH; Denniston AK; Chalker A; Raatz H; Armstrong N; Shah D; Witlox W; Worthy G; Noake C; Riemsma R; Kleijnen J; Joore MA
Pharmacoeconomics; 2020 May; 38(5):431-441. PubMed ID: 31701471
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Grossi F; Costa F
Clin Ther; 2020 May; 42(5):830-847. PubMed ID: 32354495
[TBL] [Abstract][Full Text] [Related]
32. Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective.
Simpson EL; Davis S; Thokala P; Breeze PR; Bryden P; Wong R
Pharmacoeconomics; 2015 Nov; 33(11):1187-94. PubMed ID: 26017401
[TBL] [Abstract][Full Text] [Related]
33. Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisal.
Beale S; Dickson R; Bagust A; Blundell M; Dundar Y; Boland A; Marshall E; Plummer R; Proudlove C
Pharmacoeconomics; 2013 Dec; 31(12):1121-9. PubMed ID: 24114739
[TBL] [Abstract][Full Text] [Related]
34. Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Gallacher D; Armoiry X; Auguste P; Court R; Mantopoulos T; Patterson J; De Santis M; Cresswell J; Mistry H
Pharmacoeconomics; 2019 Jan; 37(1):19-27. PubMed ID: 30030817
[TBL] [Abstract][Full Text] [Related]
35. Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Wijnen B; Witlox W; Wolff R; Fayter D; Ramaekers B; Otten T; Ryder S; Posadzki P; Worthy G; Stirk L; Armstrong N; Kleijnen J; Joore M
Pharmacoeconomics; 2023 Jan; 41(1):33-42. PubMed ID: 36301414
[TBL] [Abstract][Full Text] [Related]
36. Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Fleeman N; Abdulla A; Bagust A; Beale S; Richardson M; Stainthorpe A; Boland A; Kotas E; McEntee J; Palmer D
Pharmacoeconomics; 2018 Mar; 36(3):289-299. PubMed ID: 29178025
[TBL] [Abstract][Full Text] [Related]
37. Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective.
Fleeman N; Bagust A; Beale S; Boland A; Dickson R; Dwan K; Richardson M; Dundar Y; Davis H; Banks L
Pharmacoeconomics; 2015 Sep; 33(9):893-904. PubMed ID: 25906420
[TBL] [Abstract][Full Text] [Related]
38. Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC; de Groot S; Riemsma R; Fayter D; Armstrong N; Portegijs P; Duffy S; Kleijnen J; Al MJ
Pharmacoeconomics; 2019 Feb; 37(2):141-153. PubMed ID: 30194622
[TBL] [Abstract][Full Text] [Related]
39. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Brown T; Boland A; Bagust A; Oyee J; Hockenhull J; Dundar Y; Dickson R; Ramani VS; Proudlove C
Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494
[TBL] [Abstract][Full Text] [Related]
40. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
